- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Urothelial carcinoma (UC)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 671KB)
Nivolumab – November 2024
Nivolumab; Injection concentrate for I.V. infusion 40 mg in 4 m L Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
30 May 2025